Ultragenyx Pharmaceutical Inc.

Contributing Author

Recent Articles by Ultragenyx Pharmaceutical Inc.

6 hours	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy RARE GlobeNewswire
Mar-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Mar-12	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency RARE GlobeNewswire
Feb-23	Ultragenyx to Participate at Investor Conferences in March RARE GlobeNewswire
Feb-23	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) RARE GlobeNewswire
Feb-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Feb-12	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update RARE -12.68% RARE GlobeNewswire
Feb-05	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update RARE GlobeNewswire
Feb-03	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) RARE GlobeNewswire
Jan-30	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA RARE GlobeNewswire
Jan-23	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jan-12	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference RARE +8.26% GlobeNewswire
Jan-07	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference RARE +7.36% GlobeNewswire
Dec-30	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) RARE +15.52% GlobeNewswire
Dec-29	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta RARE -42.32% GlobeNewswire
Dec-19	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Nov-24	Ultragenyx to Participate in Investor Conferences in December RARE GlobeNewswire
Nov-21	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE +7.73% GlobeNewswire
Nov-04	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Nov-04	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences RARE GlobeNewswire
Oct-30	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups RARE GlobeNewswire
Oct-28	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Oct-24	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE +5.31% RARE GlobeNewswire
Oct-03	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Sep-30	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President RARE GlobeNewswire
Sep-19	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Sep-08	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) RARE GlobeNewswire
Aug-29	Ultragenyx to Participate at Investor Conferences in September RARE +6.91% RARE GlobeNewswire
Aug-21	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Aug-18	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) RARE GlobeNewswire
Aug-05	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-31	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome RARE GlobeNewswire
Jul-30	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-18	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jul-14	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) RARE GlobeNewswire
Jul-11	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) RARE GlobeNewswire
Jul-09	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis RARE -25.11% RARE +5.12% GlobeNewswire
Jun-27	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome RARE GlobeNewswire
Jun-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jun-03	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference RARE GlobeNewswire
May-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE -5.19% RARE GlobeNewswire
May-14	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report RARE GlobeNewswire
May-07	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference RARE +7.66% RARE GlobeNewswire
May-06	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update RARE -9.80% GlobeNewswire

Ultragenyx Pharmaceutical Inc.

Recent Articles by Ultragenyx Pharmaceutical Inc.

Upgrade your Finviz experience